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ABSTRACT
The Cancer Immunoediting concept has provided critical insights suggesting dual 
functions of immune system during the cancer initiation and development. However, 
the dynamics and roles of CD4+ and CD8+ T cells in the pathogenesis of breast cancer 
remain unclear. Here we utilized two murine breast cancer models (4T1 and E0771) 
and demonstrated that both CD4+ and CD8+ T cells were increased and involved in 
immune responses, but with distinct dynamic trends in breast cancer development. 
In addition to cell number increases, CD4+ T cells changed their dominant subsets 
from Th1 in the early stages to Treg and Th17 cells in the late stages of the cancer 
progression. We also analyzed CD4+ and CD8+ T cell infiltration in primary breast 
cancer tissues from cancer patients. We observed that CD8+ T cells are the key effector 
cell population mediating effective anti-tumor immunity resulting in better clinical 
outcomes. In contrast, intra-tumoral CD4+ T cells have negative prognostic effects 
on breast cancer patient outcomes. These studies indicate that CD4+ and CD8+ T 
cells have opposing roles in breast cancer progression and outcomes, which provides 
new insights relevant for the development of effective cancer immunotherapeutic 
approaches.
INTRODUCTION
Breast cancer is the second leading cause of cancer-
related death in women worldwide. Significant progress 
has been made in the diagnosis and treatments of human 
breast cancer, but clinical outcomes of patients are still 
discouraging [1, 2]. Immunotherapy is a highly attractive 
alternative approach to treat patients with advanced breast 
cancer [3-9]. Increasing evidence suggests that interplay 
between immune cells and tumor cells exerts a major 
influence on breast tumor development and progression 
[10]. Furthermore, recent “Cancer Immunoediting” 
concept provided insights that immune system has 
both immune surveillance and tumor promotion effects 
during the cancer development [11-14]. Thus, a better 
understanding of the dynamic roles and pathogenesis 
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of immune cells, especially T cells in breast cancer is 
essential for the development of novel strategies to treat 
cancer patients.
It is established that an effective anti-tumor immune 
response requires the involvement of both CD4+ and CD8+ 
T cells [11-14]. The role of CD4+ T cells in anti-tumor 
immunity has recently been extensively studied in both 
pre-clinial animal models and and clinical cancer patients. 
CD4+ T cells are critical for priming of tumor-specific 
CD8+ T cells and for the seconary expansion and memory 
of CD8+ T cells as well [15, 16]. However, the discovery of 
regulatory T cells (Treg) and Th17 cells not only changes 
the classical Th1/Th2 paradigm of Th cell differentiation, 
but also markedly alters conventional thinking regarding 
the role of CD4+ T cells in anti-tumor immunity [17-21]. 
It has been shown that tumor-infiltrating Treg cell-induced 
immunosuppressive microenvironment prevents effective 
anti-tumor immunity and becomes a major obstacle to 
the success of immunotherapy against breast cancer [21-
25]. Furthermore, the functional contribution of human 
Th17 cells to tumor immunity remains controversial 
since both pro- and anti-tumor effects have been observed 
varied among tumor types [19, 20]. Therefore, improved 
understanding of the nature and functional roles of these 
CD4+ T cell subsets in tumor immunity during the course 
of breast cancer development is important for effective 
treatments of breast cancer. However, little is known 
about the dynamic and fuctional alterations of these T 
cell subsets in the immunoediting processes during breast 
cancer progression. In addition, very little information is 
available for the understanding of which T cell subset is 
the determinant for clinical outcomes of breast cancer.
Increasing evidence suggests that tumor-specific 
tumor-infiltrating T cells (TILs) but not circulating T 
cells predict clinical outcomes of cancer patients [26-28]. 
Studies from the retrospectively analyzed clinical tumor 
tissues of breast cancer patients further demonstrated 
that tumor-infiltrating CD8+ T cells and FoxP3+ T 
cells are important components for assessing disease 
prognosis and clinical progression [29-32]. However, the 
dynamic distribution and quantity of these T cell subsets 
in different organs and tumor tissues with the tumor 
progression have not been reported in breast cancer. 
Suitable animal models are required to precisely determine 
prognostic roles of CD4+ and CD8+ T cells with different 
distribution origins in breast cancer, which should not 
only provide new prognostic information but also be a 
key for the development and clinical application of novel 
immunotherapeutic strategies in human breast cancer. 
To better understand the roles of CD4+ and CD8+ 
T cells in the pathogenesis of breast cancer, we utilized 
4T1 and E0771, two distinct mouse breast cancer models 
to mimic different clinical stages of human breast cancer. 
We further characterized the dynamic distributions of 
CD4+ T cell subsets and CD8+ T cells in different organs 
with varied cancer developmental stages in these two 
mouse models. We showed that both CD4+ and CD8+ T 
cells involved the immune responses but with distinct 
dynamic trends in breast cancer development, suggesting 
their potentially different roles in directing breast cancer 
progression. In addition to cell number increases, CD4+ T 
cells changed their dominant subsets from Th1 in the early 
stages to Treg and Th17 cells in the late stages of the breast 
cancer development. Moreover, we determined CD4+ T 
cell subset and CD8+ T cell infiltration in primary breast 
cancer tissues from cancer patients and retrospectively 
analyzed their correlations with prognostic factors and 
clinical outcomes. Our results further confirmed that 
CD8+ T cells are the key effector cell population and 
have positive effects on anti-tumor immunity and patient 
clinical outcomes, and that CD4+ and CD8+ T cells have 
opposing prognostic effects for breast cancer patient 
outcomes. These studies collectively suggest the dynamics 
and opposing roles of CD4+ and CD8+ in directing breast 
cancer progression and outcomes. 
RESULTS
Accumulation of both CD4+ T and CD8+ T 
cells but with different trends in the tumor 
microenvironment during breast cancer 
development and progression
To better understand the interactions and role of 
immune system in the pathogenesis of breast cancer, two 
distinct murine mammary cancer cell lines 4T1 and E0771 
with different pathologic types were selected to establish 
breast cancer models for our studies. 4T1 cells originally 
isolated from BALB/c mice is a good model for metastatic 
and advanced stages of breast cancer developing tumor 
with a rapid progression [33]. While E0771 cell is 
medullary breast adenocarcinoma cells from C57BL/6 
mice, representing a good model for spontaneously 
developed breast cancer [34]. To mimic different tumor 
stages of cancer progression in the clinical cancer patients, 
varied tumor sizes instead of growth times were utilized 
for the time points in this study (Figure 1A). When tumor 
volumes reached the indicated sizes after tumor challenge, 
T cell numbers and proportions were analyzed in the 
different organs and tumor sites. Gradually increased cell 
proportions and absolute numbers of tumor-infiltrating 
CD4+ and CD8+ T cells were observed in both 4T1 and 
E0771 tumor-bearing mice with the increasing tumor size 
and progression, indicating accumulation of both CD4+ 
and CD8+ T cells into tumor sites (Figure 1B and 1C). 
To exclude the possibility that increased absolute T cell 
numbers are due to the enlarged tumors, the relative cell 
numbers per tumor volume of CD4+ and CD8+ TILs were 
further determined at different tumor stages. We observed 
consistent trends as shown in the absolute numbers that 
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Figure 1: Accumulation of both CD4+ and CD8+ T cells in the TILs during tumor development and progression in 
breast cancer mouse models. A. Tumor growth curves of mouse breast cancer 4T1 and E0771 cells were determined based on tumor 
sizes. 4T1 (1×105 cells/mouse) and E0771 (2×105 cells/mouse) were implanted into mammary gland fat pads of female BALB/c and 
C57BL/6 mice (n = 4), respectively. When primary tumors reached indicated sizes, tumor-bearing mice and tumor free-littermate controls 
were sacrificed, TILs were isolated and cell proportions and numbers analyzed. B. The proportions of CD4+ and CD8+ T cells in TILs were 
analyzed at the indicated time points using flow cytometry analyses by gating CD3+ population. Results shown are a representative graph 
of 4 tumor-bearing mice. C. Increased absolute cell numbers of both CD4+ and CD8+ TILs with the tumor progression. Tumor-infiltrating 
CD4+ and CD8+ T cells were calculated based on their proportions in CD3+ T cells and total cell numbers in each digested tumor tissue. D. 
Relative cell numbers of both CD4+ and CD8+ TILs with the tumor progression were calculated based on their absolute cell numbers per 
tumor volume in each tumor tissue. E. Dynamic changes of CD4+ to CD8+ T cell ratios at the different stages of tumor development. Result 
of each dot shown in D. and E. is derived from an individual mouse. Data shown are mean ± SE from four mice in each time point. *p < 
0.05 and **p < 0.01 between the indicated two groups determined by paired student’s t test. Data shown in A. to E. are representative from 
three independent experiments with similar results.
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relative cell numbers of CD4+ and CD8+ TILs were also 
significantly increased in both 4T1 and E0771 mouse 
models during the course of tumor development (Figure 
1D). However, we found that CD4+ and CD8+ TILs had 
distinctly different patterns during tumor progression, 
indicating different roles of these two cell populations 
in the pathogenesis of breast cancer (Figure 1B-1D). In 
the early stages of tumor development (before 16 days in 
4T1 and 22 days in E0771 models), CD8+ T cells were 
more dominant than CD4+ T cells in TILs; while the 
reversed proportion was observed in the late stages of 
tumor development. Furthermore, more rapidly increased 
infiltration of CD4+ T cells than that of CD8+ T in the 
tumor sites was observed with the tumor progression 
(Figure 1D). These results were further confirmed in the 
analyses of the CD4/CD8 T cell ratios in the different 
tumor stages based on their proportions and absolute 
cell numbers in TILs. As expected, markedly increased 
CD4/CD8 ratios at the late tumor stages were observed 
compared with those in the early tumor stages in both 4T1 
and E0771 breast tumor models (Figure 1E). Collectively, 
both CD4+ and CD8+ T cells were accumulated in the 
tumor microenvironment but with different increased 
trends during breast cancer development and progression. 
We also determined whether the phenomena and 
alterations of CD4+ and CD8+ T cells observed in TILs 
were also applied to the T cells in the peripheral organs, 
including in peripheral blood, spleen and draining lymph 
nodes. We found similar trends of CD4+ and CD8+ T cells 
in bloods as those in TILs, showing significantly increased 
CD4/CD8 T cell ratios with the advanced tumor stages 
both in 4T1 and E0771 mouse models (Supplemental 
Figure 1A). However, the trends and phenomena were not 
observed in CD4+ and CD8+ T cells obtained from spleens 
and lymph nodes in both tumor models (Supplemental 
Figure 1B and 1C). These data suggested that varied 
changes and different roles of T cells may exist which 
depend on their origins and organ locations. 
Dynamics and distinct distributions of tumor-
infiltrating CD4+ T cell subsets during breast 
cancer development and progression
Accumulating evidence suggest that CD4+ T 
cells play a critical role for tumor immunity and each 
subset has a unique role in adaptive immune during 
the tumor development [11-14]. Given that our results 
showed significantly increased CD4+ T cell proportion 
and numbers in TILs of late stages of breast cancer 
progression, we reasoned that CD4+ T cell subsets and their 
roles may alter during breast cancer progression, resulting 
in tumor promotion rather than tumor surveillance. To test 
this possibility, we evaluated the dynamic distributions 
of CD4+ T cell subsets based on their proportions and 
relative cell numbers per tumor size at different stages 
of cancer development in these two breast cancer models 
(Supplemental Figure 2A and 2B). We expectedly 
observed that tendency of CD4+IFN-γ+ T cells, both in 
fraction and relative cell numbers were significantly 
increased in the early and middle cancer stages. However, 
both then were declined with the advanced stages in the 
two breast tumor models, suggesting their important role 
as effector T cells involved in early tumor surveillance 
(Figure 2A-2D). Furthermore, in the E0771 model, the 
peak of CD4+IFN-γ+ was observed much earlier than 
that in the 4T1 tumor model with tumor progression, 
suggesting the dynamic differences of Th1 cells in 
these two models (Figure 2C and 2D). For IL-4+CD4+ 
subset, although it also showed decreased proportions, 
no significant difference was observed in its relative cell 
numbers in both 4T1-bearing and E0771-bearing mice 
(Figure 2A-2D). Notably, not only the proportion but 
also total cell numbers of IL-4+CD4+ cells remained in a 
relatively low level among TILs during the breast cancer 
development, suggesting that Th2 subset is a subdominant 
subset compared with the other T cell subsets ( < 4%) 
(Supplemental Figure 2C). 
Th17 cells have been extensively studied in mouse 
tumor models and human cancer patients during the past 
several years, but conclusions regarding the functional role 
of Th17 cells in tumor immunity remain controversial [19]. 
Our previous studies have shown increased Th17 cells in 
human breast cancer TILs [35, 36]. We observed that the 
proportion and relative cell numbers of CD4+IL-17+ subset 
dramatically went up at the early stage and reached a peak 
at the middle cancer stage, and then significantly dropped 
down at the late stage of tumor progression in both 4T1 
(Figure 2A and 2B) and E0771 tumor models (Figure 
2C and 2D). CD4+IL-17+ T cell subset had a similar 
tend as that of CD4+IFN-γ+ subset in the absolute cell 
numbers following the tumor development (Supplemental 
Figure 2C), but its percentage and relative cell numbers 
maintained relative higher levels in the late cancer stage 
compared with IFN-γ+CD4+T cells (Figure 2A-2D). The 
results suggest that Th17 cells become a dominant CD4+ 
T cell population in TILs of breast cancer. 
It has been clear that FoxP3+ Treg-induced immune 
suppression is the major obstacle for successful anti-
tumor immunity [21-25]. In contrast to the other T cell 
subsets, FoxP3+CD4+ Treg subpopulation had a constantly 
higher proportion (10-40%) in CD4+ T cell subsets from 
initial stage to late stage with the tumor progression 
(Figure 2A and 2C). More strikingly, its proportion and 
relative cell numbers both showed significant increases 
following tumor progression and reached the highest 
level at the late cancer stage in both 4T1 and E0771 tumor 
models (Figure 2A-2D). In addition, absolute Foxp3+ 
Treg cell numbers revealed a rapid increase compared 
with that of the other T cell subsets in the tumor sites 
(Supplemental Figure 2C), further confirming that Treg 
cells are the most dominant CD4+ T cell subset forming 
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Figure 2: Dynamics of tumor-infiltrating CD4+ T cell subsets in mouse breast cancer models. A. and C. Proportions of CD4+ 
T cell subsets in TILs were analyzed at the indicated time points using flow cytometry analyses by gating CD4+ population. The treatment 
procedure was identical as that described in Figure 1. TILs were isolated and intracellular staining performed after stimulation with PMA 
and ionomycin for 5 hours. B. and D. Relative cell numbers of CD4+ T cell subsets with the tumor progression were calculated based on 
their absolute cell numbers per tumor volume in each tumor tissue. E. Dynamic changes of Foxp3+CD4+ to CD8+ T cell ratios were analyzed 
based on the proportions of CD4+Foxp3+ subset and CD8+ TILs. Result of each dot shown in A. to E. is derived from an individual mouse. 
Data shown are mean ± SE from four mice in each time point. *p < 0.05 and **p < 0.01 between the indicated two groups determined by 
paired student’s t test. Data shown in A. to E. are representative from three independent experiments with similar results.
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a tumor suppressive microenvironment at late stage of 
tumor progression. Given that significant increase of 
CD4/CD8 ratio was observed in the late stage of breast 
tumor models (Figure 1E), we therefore determined the 
alterations of Foxp3+CD4/CD8 T cell ratios in the different 
tumor developmental stages. As expected, Foxp3+CD4/
CD8 ratios were dramatically increased with the tumor 
progression in both tumor models (Figure 2E). These data 
clearly suggested that the accumulation and increase of 
CD4+ TILs cells in the late breast tumor stages is due to 
the increases of Th17 and Treg cell populations. 
Distinct distributions of CD4+ T cell subsets in 
peripheral organs in breast tumor-bearing mice
We next determined whether CD4+ T cell subsets 
in the other organs could have similar profiles as those 
in the tumor sites. The dynamic distributions of CD4+ T 
cell subsets in peripheral blood, spleen and draining lymph 
nodes were analyzed in both normal and tumor-bearing 
mice. In tumor-free C57BL/6 and BALB/c control mice, 
there were very limited proportions of CD4+ T cell subsets 
in peripheral blood (Figure 3A and 3B). However, after 
the tumor challenge, all CD4+ T cell subsets in blood 
had sharp increases at the early stage and then followed 
to rapidly drop down at the middle or late cancer stages 
in 4T1 and E0771 tumor-bearing mice, suggesting the 
hematological changes of CD4+ T cell subsets (Figure 3A 
and 3B). Moreover, compared with tumor-free control, 
significant increased numbers of white blood cells (WBC) 
were observed in the peripheral blood of 4T1-bearing mice 
but not in E0771-bearing mice (Supplemental Figure 3A). 
In addition to the blood, all four T cell subsets markedly 
increased in tumor draining lymph nodes at the late stage 
of 4T1 tumor progression (Figure 3C). Whereas in E0771-
bearing mice, only CD4+IL17+ and CD4+Foxp3+ subsets 
had significant increases in tumor draining lymph nodes 
(Figure 3D). Furthermore, tumor draining lymph nodes 
of the both breast cancer models harbored high levels of 
FoxP3+Treg subset, which reached the maximal levels 
at the late cancer stage (Figure 3C and 3D). Notably, all 
CD4+ T cell subsets remained at very low proportions 
in the spleens in both tumor models, although they had 
varied distribution levels during tumor development 
(Supplemental Figure 3B and 3C). These studies clearly 
suggested that distribution profile of CD4+ T subsets in 
the peripheral organs cannot predict that in the tumor 
microenvironment. 
Prevalence of both CD4+ and CD8+ T cells in situ 
in human breast cancer tissues
Our findings from mouse breast cancer models 
suggested that both CD4+ and CD8+ T cells significantly 
infiltrated into tumor sites. To further confirm the role 
of CD4+ and CD8+ T cells in human breast cancer 
development and progression, we assessed CD4+ and 
CD8+ T cells, as well as IL-17+ and Foxp3+ cells in 
breast tumor tissues from cancer patients using the 
immunohistochemical staining (Figure 4A). In normal 
breast tissues, very low levels of T cells were detected. In 
contrast, significantly increased numbers of both CD4+ and 
CD8+ T cells were detected in breast tumor tissues, which 
were consistent with the findings in mouse breast cancer 
models (Figure 4B). In parallel experiments, we found 
that very high percentages of IL-17+ and FoxP3+ cells 
also existed in breast cancer tissues compared with those 
in normal breast tissues (Figure 4A and data not shown). 
Linear correlation analyses further demonstrated that both 
IL-17+ and FoxP3+ cells were significantly positively 
correlated with CD4+ TILs (Figure 4C). Notably, relative 
to IL-17+ cells (r = 0.379; P = 0.0093), Foxp3+ cells had 
a more significant correlation with CD4+ TILs (r = 0.639; 
P = 1.4 x10-10) in breast cancer patients. These results 
collectively suggested that both FoxP3+ and IL-17+ T 
cells are important components of TILs in breast cancer 
patients, and that the increase and activation of FoxP3+ 
Treg cells is an important strategy for tumor escaping from 
anti-tumor immunity during tumor development. 
Associations of CD4+ and CD8+ T cells with 
clinicopathologic factors of breast cancer patients
Given that immune system has duel roles of tumor 
surveillance and promotion during the tumor development 
[11-14], we investigated clinical significance of CD4+ and 
CD8+ T cells in human breast cancer. Clinicopathological 
factors of breast cancer patients were retrospectively 
analyzed relative to the levels of the intra-tumoral CD4+ 
and CD8+ T cells as well as CD4/CD8 ratios. In addition, 
cancer-specific survival rates for patients were analyzed 
in correlation with T cells (CD4+, CD8+, FoxP3+ and IL-
17+ T cells). As shown in Table 1, intra-tumoral CD4+ T 
cell numbers were positively correlated with advanced 
tumor stages (p = 2.75 x 10-5), large tumor sizes (p = 
0.01), positive lymph node status (p = 0.003) and HER2 
expression (P = 0.03). In contrast, CD4+ T cell infiltration 
was inversely correlated with RFS (p = 0.07) of breast 
cancer patients. In addition, we also confirmed that 
numbers of tumor-infiltrating FoxP3+ cells in breast 
cancer were also positively correlated with tumor stages 
and lymph nodal status, but strongly negatively correlated 
with relapse-free survival (RFS) and overall survival 
(OS) [37]. Interestingly, we did not find any correlation 
between numbers of tumor-infiltrating IL-17+ cells and 
clinicopathological parameters in breast cancer patients 
(Data not shown). These results combined with the 
findings from mouse models suggest that tumor-infiltrating 
CD4+ T cells have dynamic subsets during tumor 
progression, which may function as a tumor promoter in 
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Figure 3: Distributions of CD4+ T cell subsets in peripheral blood and draining lymph nodes in breast tumor-bearing 
mice. The dynamic distributions of CD4+ T cell subsets in blood (A. and B.) and draining lymph nodes (C. and D.) from breast tumor-
bearing mice in two models were analyzed at the indicated time points using flow cytometry analyses by gating CD4+ population. Tumor-
free BALB/c (4T1) and C57BL/6 (E0771) mice were included as controls. The treatment procedure was identical as that described in Figure 
1. T cells were isolated from the organs and intracellular staining performed after stimulation with PMA and ionomycin for 5 hours. Results 
shown in A. to D. are mean ± SE from four individual mice in each time point. *p < 0.05 and **p < 0.01 between the indicated two groups 
determined by paired student’s t test. Data shown in A. to D. are representative from three independent experiments with similar results.
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the late cancer stage. 
Tumor-infiltrating CD8+ T cells have been shown to 
be an important biomarker for predicting clinical outcome 
in human breast cancer [32]. As expected, we observed that 
tumor-infiltrating CD8+ T cells were inversely correlated 
with advanced tumor stages (p = 0.02) and positive lymph 
node status (p = 2.84 × 10-3), as well as were significantly 
positively correlated with clinical outcomes of RFS (p = 
2.67 × 10-5) and OS (p = 1.14 × 10-3) (Table 1). These 
results further indicated different effects mediated by 
CD4+ and CD8+ TILs in anti-tumor immunity and clinical 
outcomes of breast cancer, and that CD8+ is the most 
critical effector cells. Meanwhile, we also analyzed the 
CD4/CD8 ratios with those factors and observed that CD4/
CD8 ratios were also strongly positively correlated with 
advanced tumor stages (p = 1.25 × 10-4), large tumor sizes 
(p = 0.04) and positive lymph node status (p = 5.58 × 10-4), 
but negatively correlated with RFS (p = 5.35 × 10-4) and 
OS (p = 4.92 × 10-3) (Table I), suggesting that CD4/CD8 
ratio is an useful and significant prognostic biomarker for 
assessing clinical outcomes of human breast cancer. 
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Opposing roles of CD4+ and CD8+ T cells in breast 
cancer progression and outcome
To further investigate the possible divergent roles of 
tumor-infiltrating CD4+ and CD8+ T cells in breast cancer 
development, we performed univariate Cox proportional 
hazard regression analyses of the relationships 
between CD4+ and CD8+ T cell levels, other prognostic 
clinicopathological factors and clinical outcomes in breast 
cancer patients. We found that lymph node status, tumor 
stage, tumor-infiltrating CD4+ and CD8+ T cell numbers, 
and CD4/CD8 ratio were all significant factors for the 
prediction of breast cancer outcomes (Supplemental Table 
1A). We also performed multivariate Cox regression 
analyses and confirmed that tumor-infiltrating CD8+ T 
cell levels had independent effects on both OS and RFS 
Figure 4: Accumulation of CD4+ and CD8+ T cells in clinical breast cancer tissues. A. Representative immunohistochemical 
staining of CD4+, CD8+ T cells, as well as IL-17+ and FoxP3+ cells in normal breast and cancer tissues. Frozen or paraffin-embedded tissue 
sections were immunohistochemically stained to detect the indicated cells. B. Significant increase numbers of CD4+ and CD8+ T cells 
in breast cancer tissues (n = 81) compared with normal breast tissues (n = 46). Numbers of CD4+ and CD8+ T cells shown are average 
numbers per high field (magnification 400×) in each tissue sample. The median number of T cells in each group is shown as a horizontal 
line. Significance was determined by unpaired t test. C. Scatter diagram analyses showing positive correlations between CD4+ T cells 
and IL-17+ and FoxP3+ cells in breast cancer tissues. Different types of TILs in frozen sections of breast tumor samples (n = 46) were 
immunohistochemically determined as described in A.. 
Oncotarget17471www.impactjournals.com/oncotarget
(Supplemental Table 1B). In addition, Kaplan-Meier 
analyses further demonstrated that the 5-year OS and 
RFS probabilities were both above 80% in CD4+ T cells 
≤16 (median expression levels in cancer tissue) cancer 
patients, whereas only about 50% of OS and RFS in 
CD4+ T cells > 16 patients (Figure 5A). In contrast to 
CD4+ T cells, if CD8+ T cells were above 13, 5-year OS 
probability was around 90% and RFS rate was above 95% 
in cancer patients, whereas only 45% of OS and 50% of 
RFS in CD8+ T cells ≤13 cancer patients (Figure 5B). 
Furthermore, we obtained that breast cancer patients with 
high levels of CD4/CD8 ratio ( > 1.2) had significantly 
poor cancer-specific OS and RFS probabilities, which was 
very similar as those in CD4+ T cells (Figure 5C). We also 
determined whether CD4+ and CD8+ T cells had different 
roles and prognostic value for clinical outcomes in breast 
cancer patients with different ER or HER2 expression 
status. However, Kaplan-Meier analysis results showed 
that CD4+ and CD8+ T cells as well as CD4/CD8 ratios in 
ER+ and HER2+ patients had very similar patterns for the 
predictions of clinical outcomes as those in the total breast 
cancer patients, suggesting that roles of both CD4+ and 
CD8+ T cells in breast cancer pathogenesis and progression 
are independent of ER and HER2 expression (Data not 
shown). Taken together, our results clearly indicate that 
CD4+ and CD8+ T cells have distinctly different roles in 
controlling breast cancer progression and outcomes.
In addition to retrospectively analyzing the 
associations with OS and RFS in breast cancer patients, 
we further determined the prognostic value of intra-
tumoral CD4+ and CD8+ T cells for the prediction of 
risk of breast cancer development during the follow-up 
period. As shown in Figure 6A, there were significantly 
increased cumulative hazard ratios with the increasing 
follow-up years for mortality and relapse in the cancer 
patients containing high levels of tumor-infiltrating CD4+ 
T cells (CD4+ T cells > 16). In contrast, cancer patients 
containing low levels of tumor-infiltrating CD4+ T cells 
(≤16) had decreased mortality ( < 30%) and relapse ( < 
20%) throughout the entire 5 year follow-up. Furthermore, 
the level of tumor-infiltrating CD8+ T cells was also an 
important prognostic factor for the prediction of breast 
cancer development. Cancer patients containing high 
levels of tumor-infiltrating CD8+ cells ( > 13) had 
significantly low mortality and relapse with cumulative 
hazards of 0.1 and 0.05, respectively throughout the 
entire 5 year follow-up, whereas patients containing 
low levels of CD8+ cells (≤13) may die or relapse with 
a cumulative hazard of 0.7 (Figure 6B). Notably, intra-
tumoral CD4/CD8 ratio is still a significant and valuable 
clinical biomarker for identifying the risk for late-relapse 
and survival of breast cancer patients. Cancer patients 
containing low levels of CD4/CD8 ratio (≤1.2) had 
significant very low mortality and relapse with cumulative 
hazards below 0.05 throughout the entire 5 year follow-
up (Figure 6C). These results further suggest that intra-
tumoral CD4+ and CD8+ T cells have opposing prognostic 
roles in controlling breast cancer development. 
DISCUSSION
Dissecting the dynamics and functional roles 
of different subsets of TILs in the tumor suppressive 
microenvironment should facilitate our better 
understanding of immunopathogenesis of cancer and 
the development of effective strategies for anti-tumor 
immunotherapy. Although the “cancer immunoediting” 
concept has precisely described how host immune system 
dynamically interacts with tumor cells and its dual roles on 
tumor development and progression in general, identifying 
the replicability of this principal in individual cancer type 
is critical for the effective clinical interventions [11-14]. 
In the current study, we investigated CD4+ T cell subsets 
and CD8+ T cells in tumor sites and other multiple organs 
during the course of tumor development and progression 
in two breast cancer models. Our results suggested that 
both CD4+ and CD8+ T cells are dynamically involved 
in the immune responses in breast cancer. In the early 
stage of breast tumor development, Th1 and CD8+ T cells 
were dominant populations in TILs which may perform 
immunosurveillance. However, in the late cancer stage, 
CD4+ TILs significantly increased in numbers and its 
dominant subsets changed to Treg and Th17 cells, which 
may contribute to tumor promotion. Moreover, our 
results from breast cancer patients confirmed that CD8+ 
T cells are the key effector cells for anti-tumor immunity 
and positively associated with better clinical outcomes. 
Furthermore, CD4+ and CD8+ T cells have opposing 
prognostic effects for breast cancer patients. These 
studies collectively suggest the dynamics and distinct 
roles of CD4+ and CD8+ T cells in directing breast cancer 
progression and outcomes. 
Identification of suitable animal models mimicking 
clinical cancers is critical for understanding the cancer 
biological behaviors and cell interactions within tumor 
microenvironments, as well as for facilitating the studies 
of preclinical assessment of cancer drug discovery and 
novel immune therapeutic strategies on human cancers. 
In this study, we utilized two distinct murine mammary 
cancer cell lines 4T1 and E0771 with different pathologic 
types to establish breast cancer models and investigate 
the dynamics of immune cells during tumor development. 
4T1 cells originally isolated from BALB/c mice share 
many characteristics with naturally occurring human 
breast cancer and metastasize to distant organs via 
the haematogenous route, making it a good model for 
mimicking the metastatic and advanced stages of human 
breast cancer [33, 38]. E0771 cell line is a medullary 
breast adenocarcinoma cell type, and syngeneic to 
C57BL/6 mice, representing the human medullary breast 
cancer with spontaneous development [34]. In our efforts 
to understand the interactions and changes of T cells with 
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Figure 5: Distinct roles of tumor-infiltrating CD4+ and CD8+ T cells in predicting clinical outcomes in breast cancer 
patients. Kaplan-Meier analyses of overall survival and relapse-free survival stratified for high and low numbers of tumor-infiltrating 
CD4+ A. and CD8+ T cells B., as well as CD4/CD8 ratios C. in breast cancer patients. The median number of indicated T cells (16 for CD4+ 
T cells, 13 for CD8+ T cells and 1.2 for CD4+/CD8+ ratios) in breast cancer tissues was used as a cutoff point to define high-number and 
low-number groups. The p values were calculated with use of the log-rank test.
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Figure 6: Prognostic values of CD4+ and CD8+ T cells, as well as CD4/CD8 ratio for the risks of breast cancer mortality 
and relapse in all breast cancer patients during the follow-up period. An increasing annual HR for mortality and relapse per 
year in the breast cancer patients (n = 81) who have high numbers of tumor-infiltrating CD4+ T cells A., low numbers of tumor-infiltrating 
CD8+ T cells B. or high CD4/CD8 ratios C. throughout the entire follow-up period. The p values were calculated with use of the log-rank 
test.
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breast tumor progression, we found that there were several 
differences of immune responses in peripheral organs 
within these two breast cancer models. We observed 
significant increased numbers of white blood cells in the 
peripheral blood of 4T1-bearing mice but not in E0771-
bearing mice during the tumor progression (Supplemental 
Figure 3A). In addition, all CD4+ T cell subsets markedly 
increased in tumor draining lymph nodes at the late 
stage of 4T1 tumor progression, whereas in E0771-
bearing mice, only CD4+IL17+ and CD4+Foxp3+ subsets 
had significant increases in tumor draining lymph nodes 
(Figure 3C and 3D). However, the overall changes and 
dynamic distributions of tumor-infiltrating CD4+ and CD8+ 
T cells had similar trends in both breast cancer models 
except the earlier peak of Th1 cells in the E0771 model 
than that in the 4T1 tumor model with tumor progression. 
Our studies suggest that both of these breast tumor models 
are useful for the studies focusing on the interactions 
between immune system and tumor cells in the tumor 
microenvironment. 
Improved understanding of the role of CD4+ T 
cells in anti-tumor immunity is challenging in tumor 
immunology research and the results have been 
controversial. Besides the traditional functions of Th1 
and Th2 cells in priming and helping tumor-specific 
CD8+ T cells and B cells, recent discovery of Th17 and 
Treg cells has not only resulted in an explosion of cancer 
immunological research but also markedly changed our 
conventional thinking of the role of CD4+ T cells in the 
pathogenesis of cancer development [17-25]. In the current 
study, we provided critical information regarding CD4+ T 
cells in the immunoeditting process during breast cancer 
development and progression both in animal models 
and in cancer patients. We first showed that numbers 
of CD4+ T cells are significantly increased with breast 
cancer development, suggesting an active involvement 
of tumor-induced immune responses. Importantly, 
besides the increase in numbers, the cell subsets of 
CD4+ T cells also dynamically changed, indicating 
distinct functions of CD4+ T cells in the different tumor 
developing stages. In early tumor stages, Th1 cells are the 
dominant population of CD4+ T cells, perhaps important 
for immunosurveillance; while in the advanced tumor 
stages, FoxP3+ Treg and Th17 cells become the dominant 
populations. It is well recognized that tumor-infiltrating 
Treg cells are a major obstacle for the success of tumor 
immunity and immunotherapy [21-25]. Therefore, our 
studies suggested that in the late tumor stage, CD4+ T cells 
may become more important for promoting tumor growth. 
This assertion was further confirmed in our retrospective 
studies in breast cancer patients, demonstrating that intra-
tumoral CD4+ T cell numbers were positively correlated 
with advanced tumor stage, large tumor sizes, and 
positive tumor metastasis, but were inversely correlated 
with survival of breast cancer patients. In addition, we 
also confirmed that numbers of tumor-infiltrating FoxP3+ 
cells in breast cancer were also positively correlated 
with tumor stages and lymph nodal status, but negatively 
correlated with RFS and OS [37]. Notably, although we 
demonstrated that Th17 cells are a dominant population in 
CD4+ TILs in both breast cancer models, we did not find 
any correlations between numbers of tumor-infiltrating 
IL-17+ cells with clinicopathological parameters in breast 
cancer patients. This may due to the small sample size in 
our current study. In addition, we observed that CD4+ T 
cell subsets have distinct distributions in peripheral organs 
(blood, spleen and lymph nodes), as in tumor sites, further 
indicating that immune profiles in peripheral organs 
cannot predict immune subsets in situ within the tumor 
microenvironment. Taken together, our studies suggest that 
CD4+ T cells have dynamic roles and subset distributions 
during breast cancer development and progression. 
Furthermore, dissecting the cell subsets and densities of 
TILs in situ in the tumor microenvironment should be 
more important and valuable for the prediction of clinical 
outcomes and the development of novel immunologic 
targeting therapies. 
Our current studies further confirmed that CD8+ 
T cells are the key effector cell population controlling 
effective anti-tumor immunity and patient clinical 
outcomes. Our studies from breast cancer mouse models 
and cancer patients clearly demonstrated significant 
accumulation of CD8+ T cells in the tumor sites. We 
observed that tumor-infiltrating CD8+ T cells were 
negatively correlated with advanced tumor stages 
and positive tumor metastasis status, but significantly 
positively correlated with clinical outcomes of RFS and 
OS. In support of our conclusions, studies from other 
groups have shown that high amounts of tumor-infiltrating 
CD8+ T cells have a favorable prognosis in breast, ovarian 
and colorectal cancers [27, 32, 39, 40]. Our results also 
suggest that tumor-infiltrating CD4+ and CD8+ T cells 
have distinct roles for control of tumor progression and 
clinical outcomes. Besides the retrospective analyses of 
breast cancer patients, the results from the two breast 
cancer murine models showed that the proportion of CD8+ 
T cells was more dominant than CD4+ T cells in TILs in 
the early stages of tumor development. However, CD4+ 
T cells more rapidly infiltrated into the tumor sites than 
CD8+ T cells with the tumor progression, and therefore 
became the more dominant population in late stages of 
tumor development (Figure 1D). Additional evidence 
supporting different roles of CD4+ and CD8+ T cells in 
the pathogenesis of breast cancer includes the dynamics 
of CD4/CD8 proportions with progression of tumor 
development. We observed markedly increased CD4/
CD8 ratios at late tumor stages compared with those 
in the early tumor stages in both 4T1 and E0771 breast 
tumor models. Furthermore, results from clinical cancer 
patients showed that CD4/CD8 ratios were strongly 
positively correlated with the advanced tumor stage, 
large tumor sizes and positive lymph node status, but 
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negatively correlated with RFS and OS. Based on these 
results, the major challenge for augmenting the success of 
anti-tumor immunity and immunotherapy against breast 
cancer is to develop effective strategies to increase CD8+ 
T cells and keep the optimal balance of CD4/CD8 in the 
tumor microenvironment. Notably, our current studies 
also indicate that intra-tumoral CD4+ and CD8+ T cells, 
as well as the ratio of CD4/CD8 in TILs are all valuable 
and significant prognostic biomarkers for predicting the 
outcomes of human breast cancer. 
MATERIALS AND METHODS
Cell lines
Breast tumor cell lines 4T1 and E0771 were 
obtained from the American Tissue Culture Collection 
(ATCC) and maintained in RPMI 1640 medium containing 
10% fetal calf serum (FCS) and penicillin-streptomycin 
(Invitrogen, Inc. San Diego, CA). 
In vivo studies
BALB/c and C57BL/6 mice (6 to 8-wk-old female) 
were purchased from The Jackson Laboratory and 
maintained in the institutional animal facility. All animal 
studies have been approved by the Institutional Animal 
Care Committee. Mouse breast tumor 4T1 (1 × 105) or 
E0771 (2 × 105) cells in 100 µl of buffered saline were 
subcutaneously injected into in the mammary fat pad of 
BALB/c (4T1) and C57BL/6 mice (E0771), respectively. 
Five to ten mice were included in each group. Tumor 
volumes were measured every 3 days. When the tumor 
volumes reached the indicated sizes in diameters (4T1: 3-5 
mm, 12-15 mm and 18-20 mm; E0771: 3-5 mm, 8-10 mm, 
12-15 mm and 18-20 mm), the tumor-bearing mice were 
sacrificed. Blood, lymph nodes (LN), spleens (SP) and 
tumor tissues were harvested and mononuclear cells were 
purified for subsequent phenotypic and cytokine profile 
analyses in vitro, as previously described [25, 41-43]. In 
addition, lymphocytes from different organs of normal 
littermates were also harvested and used as negative 
controls.
Flow cytometry analysis
The expression markers on T cells were determined 
by FACS analyses after surface or intracellular staining 
with anti-mouse specific antibodies conjugated with Alexa 
Fluor 488, PE, FITC, allophycocyanin (APC), or PerCP.
cy5.5. These mouse antibodies included: anti-CD3, anti-
CD4, anti-CD8, anti-IFN-γ, anti-IL-4, anti-IL-17, and anti-
FoxP3, which were purchased from BD Biosciences. For 
intracellular staining, T cells were stimulated with PMA 
(1 µg/ml) and ionomycin (2 µg/ml) (Sigma-Aldrich) for 
5 hours in the presence of GolgiStop (BD Biosciences) 
before the intracellular staining with antibodies. All 
stained cells were analyzed on a LSR II cytometer (BD 
Bioscience) and data analyzed with FlowJo software (Tree 
Star).
Patients and sample collection
Tumor samples were obtained from breast cancer 
patients treated at Saint Louis University Department of 
Surgery from 2004 to 2012 who have given informed 
consents for enrollment in a prospective tumor 
procurement protocol approved by the Saint Louis 
University Institutional Review Board. Total of 81 
tumor tissues from different stages of identified primary 
breast cancer were collected for this study. Whenever 
feasible without interfering with histopathologic analysis 
for ongoing clinical decision making, paired fresh 
tumor tissues and normal breast tissues were obtained 
perioperatively and snapped frozen in liquid nitogen (N 
= 46). For patients from whom fresh tissues were not 
obtained, paraffin blocks of tumor tissues were obtained 
for analysis (N = 35). Patient clinical data were also 
collected for analysis.
Immunohistochemical staining and quantification 
method
The cell populations of CD4+ and CD8+ T cells, IL-
17+ and FoxP3+ cells in cancer and normal tissues (frozen 
or paraffin-embedded sections) were determined using 
immunohistochemical staining with the Histostain®-
Plus 3rd Gen IHC Detection Kit (Invitrogen, CA), as 
we described previously [37, 42, 44]. For frozen section 
staining, the following monoclonal antibodies were used: 
mouse anti-human IL-17 (clone 1C12), FoxP3 (clone 
236A/E7), CD4 (clone RPA-T4), and CD8 (clone RPA-T8) 
(eBioscience, San Diego, CA) monoclonal antibodies, at 
diluted concentrations of 1: 50, 1: 50, 1:100 and 1:100, 
respectively. For paraffin-embedded tumor sections, the 
following monoclonal antibodies were used: FoxP3 (clone 
236A/E7), CD4 (clone BC/1F6), and CD8 (clone 144B) 
(Abcam, Boston, MA) monoclonal antibodies at a diluted 
concentration of 1: 50. Controls were performed by 
incubating slides with the isotype control antibody instead 
of primary antibodies, or second antibody alone. Normal 
breast tissues served as controls. Expressions of CD4+, 
CD8+ T cells, and IL-17+ and FoxP3+ cells in tissues were 
evaluated manually using a computerized image system 
composed of a Leica ICC50 camera system equipped on 
a Leica DM750 microscope (North Central Instruments, 
Minneapolis, MN). Twenty fields (400 ×, magnification) of 
each tumor tissue section, including both cancer nest and 
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stroma areas were counted and summed, and the means 
of positive cell numbers per field reported. The counting 
was performed by three independent investigators (C. 
Ma, J. Ye and F. Wang) who had no previous knowledge 
of the patient clinical backgrounds, and the results were 
averaged. 
Statistical analysis
For in vivo animal experiments, data are expressed 
as mean ± standard deviation (SD). The significance of 
difference between groups was determined by paired 
or unpaired two-tailed Student’s t-test or the one-
way analysis of variance (ANOVA). Differences were 
considered significant for p values less than 0.05. For 
breast cancer tissue analyses, the median expression of 
each TIL population (16 for CD4+ T cells, 12 for FoxP3+ 
cells, 8 for IL-17+ cells, and 13 for CD8+ T cells) in breast 
cancer tissues was used as a cutoff point to define the 
TIL-high and TIL-low groups, as we previously described 
[37]. Pearson’s Chi-square test was used to prospectively 
analyze the correlations between the cell number of each 
TIL and clinical features, including age, nodal status, 
tumor size, tumor stage, estrogen receptor (ER) status, 
epidermal growth factor receptor 2 (HER2) positivity, 
relapse-free survival (RFS) and overall survival (OS). OS 
was determined from the date of surgery to the date of 
death by any cause or to the date of the last follow-up. 
RFS was measured as the length of time from surgery 
to the date of relapse. For all categorical predictors 
(including the cell numbers dichotomized by medians), 
the log-rank test was used to perform univariate survival 
association analyses for OS and RFS. Survival and 
relapse-free probability and cumulative hazard associated 
with prognostic factors for OS and RFS were estimated 
by the Kaplan-Meier method, and hazard ratios were 
estimated by a Cox proportional hazard regression model. 
Data processing and statistical analyses were performed 
using SAS 9.1 and R 2.13.0. Statistical significance was 
defined when alpha < 0.05 (2-tailed).
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